Natalizumab for Active Crohn's Disease
#69 most-disruptive IBD paper
815
Citations (OpenAlex)
635
Citations (NIH iCite)
-0.003
CD₅ disruption
Bibliometrics via OpenAlex (citations) and NIH iCite (disruption graph).
This page presents bibliographic and bibliometric information only; it does not reproduce the article abstract or full text. Read the article on PubMed or via the publisher link above. This paper appears on the IBDology all-time IBD literature leaderboards.
Educational and research-reference use only — not medical advice. IBDology curates the inflammatory bowel disease literature for clinicians and researchers.